Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07842367
PHASE2

Inflammation and Medical Provider Attitudes, Cognition, and Treatment Decisions Study

Sponsor: University of Arkansas, Fayetteville

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind clinical trial involving emergency medicine and internal medicine healthcare providers as participants. The intervention involves the administration of the seasonal influenza vaccine or a saline placebo; this protocol is used in psychoneuro-immunology to simulate a state of mild illness. The primary aim is to examine whether acute inflammation induced by receiving the vaccine affects decision-making on standardized psychological reaction time tasks and questionnaires. Participants attend two laboratory sessions on consecutive days, receive either a seasonal influenza vaccine or a saline placebo at the first session, provide blood samples to measure inflammatory cytokines, and complete a series of standardized assessments of medical decision-making and social attitudes. Participants who received the placebo during the first session will receive the vaccine during the second session. Overall, the study is designed to examine how adverse provider conditions particularly acute inflammation, burnout, and concerns about one's own health affect provider judgments and healthcare-related decision-making. The primary hypothesis is that providers experiencing greater adverse conditions at the time of research participation would have altered decision-making compared to those experiencing fewer adverse conditions.

Official title: The Impacts of Adverse Provider Conditions on Medical Decision-Making and Patient Care

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2026-09

Completion Date

2027-12

Last Updated

2026-09-30

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Influenza vaccine

A single administration of a seasonal trivalent cell-based influenza vaccine delivered by injection into the arm at the end of the first study session.

OTHER

Placebo

Control group will receive a saline placebo injection at the end of Session 1

Locations (3)

University of Arkansas for Medical Sciences

Fayetteville, Arkansas, United States

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, United States

Carilion Medical Center

Roanoke, Virginia, United States